BioLineRx (BLRX) Invested Capital: 2023-2025
Historic Invested Capital for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to -$394.2 million.
- BioLineRx's Invested Capital fell 3.68% to -$394.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$394.2 million, marking a year-over-year decrease of 3.68%. This contributed to the annual value of -$395.3 million for FY2024, which is 200.41% down from last year.
- According to the latest figures from Q2 2025, BioLineRx's Invested Capital is -$394.2 million, which was down 1.06% from -$390.0 million recorded in Q1 2025.
- Over the past 5 years, BioLineRx's Invested Capital peaked at $393.8 million during Q4 2023, and registered a low of -$395.3 million during Q4 2024.
- In the last 3 years, BioLineRx's Invested Capital had a median value of -$383.5 million in 2024 and averaged -$301.1 million.
- Data for BioLineRx's Invested Capital shows a maximum YoY plummeted of 200.41% (in 2024) over the last 5 years.
- Over the past 3 years, BioLineRx's Invested Capital (Quarterly) stood at $393.8 million in 2023, then crashed by 200.41% to -$395.3 million in 2024, then fell by 3.68% to -$394.2 million in 2025.
- Its Invested Capital stands at -$394.2 million for Q2 2025, versus -$390.0 million for Q1 2025 and -$395.3 million for Q4 2024.